A Novel Approach for Treatment of COVID-19 with Convalescent Plasma Yadav Akshay R.*, Mohite Shrinivas K. Department of Pharmaceutical Chemistry, Rajarambapu College of Pharmacy, Kasegaon, Maharashtra, India-415404 *Corresponding Author E-mail: akshayyadav24197@gmail.com
Online published on 10 August, 2020. Abstract According to World Health Organization (WHO), Coronaviruses are a large family of viruses which can infect birds and mammals, including humans. At the end of 2019 in Wuhan, China, a novel coronavirus, known as 2019-nCoV, emerged. While COVID-19 and SARS-CoV belong to the same subgroup of beta corona virus, genome-level similarity is only 70 percent, and genetic differences from SARS-CoV have been identified in the novel group. Transfusion of convalescent blood products (CBP), especially convalescent plasma (CP), is useful if the latter induces neutralizing antibodies against emerging infectious agents. CBPs are extracted from a convalescent source by collecting whole blood or plasma apheresis. Passive immunization therapy was successfully implemented back to the 1890s to treat infectious diseases. An individual who is ill with infectious diseases and is recovering has blood drawn and screened for antibodies neutralizing specific microorganisms. After identifying those with high titers of neutralizing antibody, convalescent plasma containing such neutralizing antibodies can be administered to minimize symptoms and mortality in individuals with a specified clinical disease. Convalescent Plasma Transfusion (CPT) has been the subject of increasing attention, especially in the wake of large-scale epidemics. Top Keywords Coronavirus, SARS-CoV, convalescent plasma, Passive immunization. Top |